ROCKVILLE, Md., May 22, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that
it will present in a fireside chat and panel as well as host
one-on-one investor meetings at the Barclays Gene Editing &
Therapy Summit 2023 on Wednesday, May 24,
2023.
Barclays Gene Editing & Therapy Summit
2023
Date: Wednesday, May 24, 2023
Fireside Chat: 9:15 a.m. ET
Panel: Genomic Medicines – Are We Ready for
Commercialization? – Perspective from Payors at 2:40 p.m. ET
A live webcast of the fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the fireside chat and panel will be available in
the Investors section of REGENXBIO's website for approximately 30
days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology
Platform Licensees are applying the NAV Technology Platform in the
development of a broad pipeline of candidates, including late-stage
and commercial programs, in multiple therapeutic areas. REGENXBIO
is committed to a "5x'25" strategy to progress five AAV
Therapeutics from our internal pipeline and licensed programs into
pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-barclays-gene-editing--therapy-summit-2023-301830445.html
SOURCE REGENXBIO Inc.